Apheris AI is a technology company.
Apheris AI has raised $3.0M across 1 funding round.
Apheris AI has raised $3.0M in total across 1 funding round.
Apheris AI has raised $3.0M in total across 1 funding round.
Apheris AI's investors include Dig Ventures, Hana Besbes.
Apheris AI is a deep tech company that builds a federated data platform enabling secure collaboration on sensitive life sciences data without sharing raw data, powering AI model training across organizations.[1][2][3] It serves major pharmaceutical companies like AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Johnson & Johnson, Roche, Sanofi, and Takeda, as well as hospitals and biotech firms, solving the challenge of data silos caused by IP protection and privacy regulations that limit AI accuracy in drug discovery and healthcare.[1][6][7] The platform addresses proprietary data locked in private repositories by allowing computations on distributed datasets, improving ML model generalizability for applications like ADMET prediction, protein-complex modeling, and multi-modal healthcare analysis, with recent $8.25M funding signaling strong growth momentum in healthcare-focused federated AI.[1][6]
Founded in 2019 in Berlin by CEO Robin Röhm and Michael Höh, Apheris emerged from the need to enable cross-organizational data collaboration without compromising IP or privacy, driven by Röhm's vision that solving global problems like disease research requires breaking data silos.[3][5] The duo assembled a team of over 30 specialists in data science, AI, and security, launching their federated data platform in September 2021 to facilitate secure ML on distributed datasets.[3] Early traction came from deployments in top pharma environments and hospitals across four continents, including powering the AISB Network for AI drug discovery among leading biopharmas, with pivotal Series A funding from OTB Ventures and eCAPITAL accelerating secure data network expansion.[7]
Apheris rides the federated learning wave in AI-driven drug discovery and healthcare, where diverse, proprietary datasets are essential for precise models but hindered by GDPR, HIPAA, and IP concerns.[2][6] Timing aligns with exploding EU data economies (projected €550B by 2025) and AI advancements like protein structure prediction, amplified by post-pandemic demand for collaborative R&D amid siloed clinical data.[3][7] Market forces favoring it include biopharma's shift to AI consortia (e.g., AISB with eight majors) and rising cyber threats to plaintext data, positioning Apheris to influence ecosystems by standardizing secure, multi-party ML and enabling new revenue for data holders.[1][5][6]
Apheris is primed to dominate secure federated AI in life sciences, with plans to hire experts, enhance AI features like hosted foundation models for protein studies, and expand data networks.[6][7] Trends like multimodal healthcare data integration and AI regulations will propel growth, evolving its influence from tech enabler to central marketplace for monetized, privacy-safe data ecosystems. As federated platforms unlock siloed value, Apheris could redefine collaborative drug discovery, turning data barriers into precision medicine accelerators.
Apheris AI has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in September 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2022 | $3.0M Seed | Dig Ventures, Hana Besbes |